GPhA and user fees
"Lower PRICED Drugs Act" is not a comprehensive measure to address all obstacles to generic drug entry, the Generic Pharmaceutical Association says. "While GPhA supports the Stabenow-Lott legislation, Pink Sheet readers should not assume, per your headline, that the bill is a 'GPhA Wish List' that will close every loophole and address all of the generic industry's concerns regarding user fees," the association states in response to the title of a 1chart in a story in "The Pink Sheet" covering the emerging debate on generic user fees (2"The Pink Sheet" Feb. 27, 2006, p. 8). "Although the Stabenow-Lott bill is a very positive measure that addresses many unintended loopholes that delay generics from coming to market, such as abuse of the citizen petition process, there are more loopholes that remain"...
You may also be interested in...
Emerging discussions on the creation of a user fee program for generic drug review place FDA in the awkward position of potentially being seen as an arbiter of drug prices - at least indirectly
Trade group AdvaMed should be consulted on how to implement the Defense Production Act to boost testing and PPE production, CEO Scott Whitaker said in a letter to President Biden.
Following a successful offering by Prestige BioPharma in January, investors will keep their focus on another upcoming major listing by the SK Group's specialist vaccines arm SK Bioscience, which is likely to set the tone for the South Korean biopharma IPO market this year.